<- Back to digest

JBJS - 2026-10-07 - Journal Article

Survival and Reoperation After Intralesional Procedures Versus Resection and Reconstruction for Renal Cell Carcinoma Bone Metastases.

Kashyap J, Carlson LA, Garvin LE, Schoedel KE, Lohse I, Lee SJ, McGough RL, Weiss KR

retrospective cohortLOE IIIn = 105 patients, 133 metastasesN/A if not reported.

Topics

oncology
PMID: 42842636DOI: 10.2106/JBJS.25.01377View on PubMed ->

Key Takeaway

Intralesional procedures for RCC long-bone metastases carried a 2.03× greater hazard of mortality versus resection and reconstruction, but reoperation rates did not differ significantly (sHR 1.08, p=0.87).

Summary Depth

Choose how much analysis to show on this article page.

Summary

This retrospective study compared survival and reoperation outcomes between intralesional (IL) and resection-and-reconstruction (R&R) procedures for RCC long-bone metastases at a single institution from 2005–2022. Using multivariable Cox and Fine-Gray competing-risks regression, IL surgery was associated with a 2.03× greater hazard of mortality (p=0.02) but no significant difference in cumulative reoperation incidence (sHR 1.08, p=0.87). In the solitary metastasis subgroup, the mortality association was not significant (HR 1.54, p=0.49), suggesting patient selection drives outcomes.

Key Limitation

Unmeasured confounding by indication is the dominant limitation, as patients selected for IL likely had worse baseline performance status or disease burden, which could account for the observed mortality difference independent of surgical approach.

Original Abstract

BACKGROUND

The management of renal cell carcinoma (RCC) long-bone metastases often involves surgery with either resection and reconstruction (R&R) or intralesional (IL) procedures. Some literature suggests that R&R improves survival and reduces the risk of recurrence and reoperation, while IL procedures offer lower surgical morbidity and faster recovery. We compared survival and reoperation outcomes following IL versus R&R procedures for RCC long-bone metastases treated at our institution.

METHODS

We retrospectively reviewed patients with histologically confirmed RCC long-bone metastases treated surgically between July 1, 2005, and June 1, 2022. Medical charts were reviewed to collect data on demographics, treatment history, and outcomes. Multivariable Cox proportional-hazards regression and Fine-Gray competing-risks regression were used to evaluate survival and reoperation following IL and R&R procedures.

RESULTS

One hundred and five patients (68% male; mean age, 62.6 years; 96% White) with 133 metastases were included. IL surgery was not significantly associated with a greater cumulative incidence of reoperation (subdistribution hazard ratio [sHR] = 1.08, p = 0.87). Reoperations were primarily due to recurrent disease (29%) and pathologic fracture (33%) in the IL group, compared with recurrent disease (29%), pathologic fracture (14%), and wound infection (14%) in the R&R group. IL surgery was associated with a greater hazard of mortality in the overall cohort (HR = 2.03, p = 0.02), although no significant association was observed in the solitary metastasis subgroup (HR = 1.54, p = 0.49).

CONCLUSIONS

IL procedures were associated with greater mortality, although this association was not observed among patients with a solitary metastasis. Given no significant difference in the cumulative incidence of reoperation between surgical approaches, IL and R&R procedures are both reasonable treatment options in appropriately selected patients and clinical settings.

LEVEL OF EVIDENCE

Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.